Nombre del producto:4-Phthalimidobutyraldehyde

IUPAC Name:4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butanal

CAS:3598-60-5
Fórmula molecular:C12H11NO3
Pureza:95%
Número de catálogo:CM193099
Peso molecular:217.22

Unidad de embalaje Stock disponible Precio($) Cantidad
CM193099-250mg in stock ƄưŢ
CM193099-1g in stock ƞŔǕ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :3598-60-5
Fórmula molecular:C12H11NO3
Punto de fusión:-
Código de sonrisas:O=CCCCN1C(=O)C2=C(C=CC=C2)C1=O
Densidad:
Número de catálogo:CM193099
Peso molecular:217.22
Punto de ebullición:373.9°C at 760 mmHg
Nº Mdl:MFCD00454178
Almacenamiento:Store at 2-8°C.

Category Infos

Column Infos

Mavorixafor
X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.

Related Products